ZPI-Targeting Nucleic Acid Duplexes for Precise Gene Silencing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene-silencing agents, such as siRNA and micro-RNA, have limitations in effectively inhibiting the expression of specific genes like ZPI, which are associated with diseases like haemophilia, Von Willebrand disease, and Factor X Deficiency.
Innovation Solution
Development of nucleic acid compounds with specific duplex regions comprising complementary strands that are nearly identical to a portion of the ZPI gene transcript, allowing for precise gene silencing through RNA-induced silencing complexes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional small organic compounds are used to inhibit protein function, then the treatment approach is simple, but they cannot effectively silence genes responsible for diseases like haemophilia and Von Willebrand disease
Solution Approach 1:
The nucleic acid compound is divided into two complementary strands (sense and antisense) that form a duplex structure. This segmentation allows the compound to specifically target and silence the ZPI gene through RNA-induced silencing complexes, achieving effective gene silencing while managing structural complexity through modular design
Solution Approach 2:
The invention uses composite nucleic acid structures combining DNA and RNA elements with specific modifications (2'-O-methyl, phosphorothioate linkages) to create a molecule that is both stable and capable of gene silencing. This composite approach enables effective ZPI gene inhibition while addressing the complexity through optimized material composition
2Reliability
If siRNA and micro-RNA are used for gene silencing, then gene expression can be inhibited, but they have limitations in effectively inhibiting ZPI expression associated with haemophilia and Von Willebrand disease
Solution Approach 1:
The nucleic acid compound is designed with specific local characteristics including a 19-nucleotide antisense region complementary to ZPI mRNA, modified nucleosides at specific positions (2'-O-methyl), and phosphorothioate linkages at defined locations. These localized modifications optimize the compound's ability to inhibit ZPI expression specifically, making it adaptable to haemostasis disorders while maintaining targeted effectiveness
Solution Approach 2:
The invention optimizes multiple parameters of the nucleic acid compound including strand length (19 nucleotides), nucleoside modifications (2'-O-methyl at specific positions), backbone modifications (phosphorothioate linkages), and duplex structure characteristics. These parameter changes enhance the compound's efficacy in inhibiting ZPI gene expression and expand its applicability to treat haemophilia and Von Willebrand disease
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nucleic acid compounds effectively inhibit ZPI expression, providing therapeutic benefits for diseases related to haemostasis disorders, including haemophilia and Von Willebrand disease, by targeting and silencing the ZPI gene.
Implementation Method 1
a duplex region that comprises a first strand and a second strand that is at least partially complementary to the first strand, wherein said first strand is: (i) at least partially complementary to a portion of RNA transcribed from the ZPI gene
Implementation Method 2
allowing for precise gene silencing through RNA-induced silencing complexes
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides novel nucleic acid compounds suitable for therapeutic use. Additionally, the present invention provides methods of making these compounds, as well as methods of using such compounds for the treatment of various diseases and conditions.